Abstract P190: Genome-wide Association Study Suggests that Inflammation and Insulin Regulation Pathways May Mediate Lipoprotein Diameter Response to Fenofibrate

• Published in: Circulation (New York, N.Y.) N.Y.), 2012-03, Vol.125 (suppl_10)
• Main Authors: Wood, Alexis C, Aslibekyan, Stella, Strake, Robert J, Borecki, Ingrid B, Tiwari, Hemant K, Tsai, Michael Y, Hopkins, Paul N, Ordovas, Jose M, Kabagambe, Edmond K, Arnett, Donna K
• Format: Article
• Language: English
• ISSN: 0009-7322; 1524-4539
• DOI: 10.1161/circ.125.suppl_10.AP190

Abstract only Shifts in lipoprotein diameter occur in insulin resistant (IR) patients - a known risk factor for cardiovascular disease. Fenofibrate modulates lipoprotein markers in a manner which is expected to reduce the risk of adverse cardiovascular events. However inter-individual variability in response to fenofibrate is very high. We aimed to examine phenotype-variant associations with shifts in lipoprotein diameter, for each of the three fractions of lipoprotein, in response to a three-week fenofibrate trial. Participants formed the general population sample from that Genetics of Lipid Lowering Drugs and Diet Network (n=817; mean age of 48.8 ± 16.2 y). Very-low, low- and high- density lipoprotein diameters were measured using NMR spectroscopy before and after a 3-week fenofibrate treatment (160mg/day). Lipoprotein diameter change, for each fraction, was calculated using growth curve models which modeled compliance with the fenofibrate protocol. Associations between single nucleotide polymorphisms on the Affymetrix 6.0 chip and lipoprotein diameter change were assessed using mixed linear models, adjusted for age, sex, study center, and family. A Bonferroni correction for multiple testing was used, with genome wide levels of significance set at P